Sunday - May 19, 2024
Mary Ann Liebert: Efficacy and Safety of Tirzepatide in Overweight and Obese Individuals With Type 1 Diabetes
March 23, 2024
NEW ROCHELLE, New York, March 23 -- Mary Ann Liebert Inc. issued the following news release:

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the use of tirzepatide in overweight/obese adults with type 1 diabetes. Click here to read the article now (https://www.liebertpub.com/doi/10.1089/dia.2024.0050).

Tirzepatide is approved for managing type 2 diabetes. It improves glucose control, facilitates weight loss, and improves c . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products